At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
'Tis the season for coughing, sneezing and runny noses. Winter is the time of year when Canadians are most susceptible to the common cold, which is caused by viruses that infect the nose and throat.
Cold viruses are typically harmless and removed by the immune system within a week or two. However, in some people, they can persist and cause problematic infections in other organs.Cold viruses, along with other several other viruses, can infect the heart causing a condition known as myocarditis. This condition is characterized by inflammation of, and damage to, the heart muscle, compromising its ability to pump blood.
In some cases, the damage is so severe that it leads to heart failure, which occurs when the heart can no longer pump enough blood to meet the body's needs.Not much is known about viral myocarditis, the immune response in the heart or the mechanisms underpinning the transition from infection to heart failure. These knowledge gaps have precluded the development of specific and more effective treatments for viral myocarditis.
To address this, TGHRI Scientist
Dr. Slava Epelman led a study examining dendritic cells (DCs), a type of immune cell, in the heart and their role in viral myocarditis. DCs reside in a variety of other organs, such as the lungs, liver and kidneys, where they initiate the immune response to eliminate disease-causing viruses.
Dr. Epelman and his colleagues discovered that the heart contains at least five different kinds of DCs, the two most abundant of which are referred to as CD103+ cells and CD11b+ cells. Using an experimental model of viral myocarditis, they found that both CD103+ and CD11b+ cells – like DCs in other organs – are crucial for triggering an immune response to eliminate viruses infecting the heart.
The absence of these cells, especially CD103+ cells, not only suppressed the anti-virus response, but also led to significant heart damage that impaired the organ's pumping action, an early warning sign for heart failure.
"Our findings suggest that CD103+ and CD11b+ DCs are required to prevent the progression of a mild infection to full blown heart failure by triggering an effective immune response to the virus," Dr. Epelman says.
This work was supported by the Canadian Institutes of Health Research, the Heart and Stroke Foundation, the March of Dimes Canada, the Ted Rogers Centre for Heart Research, the Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, the Peter Munk Cardiac Centre, the National Institutes of Health and the Toronto General & Western Hospital Foundation. M Cybulsky holds a Tier 1 Canada Research Chair in Arterial Wall Biology and Atherogenesis.